Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dawn C Buse

Showing results (111-120 of 230) with videos related to

Pageof 23
Sort By:
Pain and Therapy|March 13, 2024
Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive ResponseDawn C Buse, Lynda J Krasenbaum, Michael J Seminerio, et al.
Headache|September 24, 2019
Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) StudyRichard B Lipton, Susan Hutchinson, Jessica Ailani, et al.
Headache|May 3, 2024
Prevalence and burden of migraine in the United States: A systematic reviewFred Cohen, Caroline V Brooks, Daniel Sun, et al.
Headache|June 5, 2025
What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United StatesFred Cohen, Caroline V Brooks, Daniel Sun, et al.
Mayo Clinic Proceedings|April 6, 2020
Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO StudySusan Hutchinson, Richard B Lipton, Jessica Ailani, et al.
Headache|October 23, 2024
Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findingsFred Cohen, Caroline V Brooks, Daniel Sun, et al.
Headache|January 21, 2026
Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi-source dataset, observational cohort studyDawn C Buse, Lindsay A Videnieks, Karissa Charles, et al.
Headache|April 18, 2015
Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) StudyDawn C Buse, Daniel Serrano, Michael L Reed, et al.
Headache|July 27, 2012
Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention StudyDawn C Buse, Aubrey N Manack, Kristina M Fanning, et al.
Therapeutic Advances in Neurological Disorders|June 6, 2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature reviewChristopher Gottschalk, Dawn C Buse, Michael J Marmura, et al.
Pageof 23

Showing results (111-120 of 230) with videos related to

Sort By:
Pageof 23
Pain and Therapy|March 13, 2024
Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive ResponseDawn C Buse, Lynda J Krasenbaum, Michael J Seminerio, et al.
Headache|September 24, 2019
Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) StudyRichard B Lipton, Susan Hutchinson, Jessica Ailani, et al.
Headache|May 3, 2024
Prevalence and burden of migraine in the United States: A systematic reviewFred Cohen, Caroline V Brooks, Daniel Sun, et al.
Headache|June 5, 2025
What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United StatesFred Cohen, Caroline V Brooks, Daniel Sun, et al.
Mayo Clinic Proceedings|April 6, 2020
Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO StudySusan Hutchinson, Richard B Lipton, Jessica Ailani, et al.
Headache|October 23, 2024
Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findingsFred Cohen, Caroline V Brooks, Daniel Sun, et al.
Headache|January 21, 2026
Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi-source dataset, observational cohort studyDawn C Buse, Lindsay A Videnieks, Karissa Charles, et al.
Headache|April 18, 2015
Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) StudyDawn C Buse, Daniel Serrano, Michael L Reed, et al.
Headache|July 27, 2012
Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention StudyDawn C Buse, Aubrey N Manack, Kristina M Fanning, et al.
Therapeutic Advances in Neurological Disorders|June 6, 2022
The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature reviewChristopher Gottschalk, Dawn C Buse, Michael J Marmura, et al.
Pageof 23